


RECEIVED

OCT 12 2001

TECH CENTER 1600/2900

Docket No. X-10576A

APPENDIX A -STATUS OF CLAIMS AND SUPPORT FOR CLAIM CHANGES PURSUANT TO 37 C.F.R. § 1.173(c)

<u>Claim</u>	<u>Status</u>	<u>Indication of Support in the Disclosure</u>
1	pending	Original patent claim
2	pending	Original patent claim
3	pending	Original patent claim
4	pending	Original patent claim
5	pending	Original patent claim
6	pending	Original patent claim
7	pending	Original patent claim
8	pending	Original patent claim
9	pending	Original patent claim
10	pending	Original patent claim
11	pending	Original patent claim
12	pending	Original patent claim
13	pending	Original patent claim
14	pending	Original patent claim
15	pending	Original patent claim
16	pending	Original patent claim
17	pending	Original patent claim
18	pending	Original patent claim
19	pending	Original patent claim
20	pending	Original patent claim
21	pending	Original patent claim
22	pending	Original patent claim
23	pending	Original patent claim
24	pending	Original patent claim
25	pending	Original patent claim

26	pending	Original patent claim
27	pending	Original patent claim
28	pending	Original patent claim
29	pending	Original patent claim
30	pending	Original patent claim
31	pending	Original patent claim
32	pending	Original patent claim
33	pending	Original patent claim
34	pending	Original patent claim
35	pending	Original patent claim
36	pending	Original patent claim
37	pending	Original patent claim
38	pending	Original patent claim
39	pending	Original patent claim
40	pending	Original patent claim
41	pending	Original patent claim
42	pending	Original patent claim
43	pending	Original patent claim
44	pending	Original patent claim
45	pending	Column 1, lines 65-67 and column 2, line 1 describe a preferred composition is a weight ratio of olanzapine to Drug Useful in the Treatment of Pain of about one(1) part olanzapine to about one (1) to about hundred (100) parts Drug Useful in the Treatment of Pain. Column 6, lines 16-19 provides further support for the composition of added claim 45.
46	pending	Column 2, lines 1-4 describe an especially preferred ratio of about one part olanzapine (1) to from about one (1) to about thirty (30) parts Drug Useful in the Treatment of Pain. Column 6, lines 19-22 provides further support for the composition of added claim 46.
47	pending	Column 2, lines 4-6 describe a further preferred ratio which may be about one part olanzapine to from about one (1) to about ten (10) parts Drug useful in the Treatment of Pain. Column 6, lines 22-24 provides further support for the composition of added claim 47.

48	pending	Column 2, lines 6-8 describe a final preferred ratio which may be about one (1) part olanzapine to about one (1) to about three (3) parts Drug Useful in the Treatment of Pain. Column 6, lines 24-26 provides further support for the composition of added claim 48.
49	pending	Column 5, lines 17-25 disclose Tylenol #3, tricyclic antidepressants (for example desipramine, imipramine, amitriptyline, nortriptyline), anticonvulsants (for example, carbamazepine, gabapentin, valproate), serotonin reuptake inhibitors (for example, fluoxetine, paroxetine, citalopram, sertraline), mixed serotonin-norepinephrine reuptake inhibitors (for example venlafaxine, duloxetine), serotonin receptor agonists and antagonists, cholinergic (muscarinic and nicotinic) analgesics, and neurokinin antagonists.
50	pending	Column 5, line 17 discloses Tylenol #3.
51	pending	Column 5, lines 16-19 disclose tricyclic antidepressants (for example desipramine, imipramine, amitriptyline, nortriptyline).
52	pending	Column 5, line 18 discloses desipramine.
53	pending	Column 5, line 18 discloses imipramine.
54	pending	Column 5, line 18 discloses amitriptyline.
55	pending	Column 5, line 19 discloses nortriptyline.
56	pending	Column 5, lines 19-20 disclose anticonvulsants (for example, carbamazepine, gabapentin, valproate).
57	pending	Column 5, line 19 discloses carbamazepine.
58	pending	Column 5, line 20 discloses gabapentin.
59	pending	Column 5, line 20 discloses valproate.
60	pending	Column 5, lines 20-21 disclose serotonin reuptake inhibitors (for example, fluoxetine, paroxetine, citalopram, sertraline).
61	pending	Column 5, line 21 discloses fluoxetine. Column 5, lines 4-6 discloses that the term "Drug Useful in the Treatment of Pain" includes a pharmaceutically acceptable salt thereof.
62	pending	Column 5, line 21 discloses paroxetine.
63	pending	Column 5, line 21 discloses citalopram.
64	pending	Column 5, line 21 discloses sertraline.
65	pending	Column 5, lines 16, and 22-23 disclose mixed serotonin-norepinephrine reuptake inhibitors (for example venlafaxine, duloxetine).
66	pending	Column 5, line 23 discloses venlafaxine.

67	pending	Column 5, line 23 discloses duloxetine.
68	pending	Column 7, lines 31-34 disclose that typical compositions include olanzapine or a pharmaceutically acceptable acid addition salt thereof and one or more Drug Useful in the Treatment of Pain associated with a pharmaceutically acceptable excipient.
69	pending	Column 7, lines 31-36 disclose that the compositions may be enclosed in a carrier.
70	pending	Column 8, line 7 discloses the composition is generally dispensed in unit form. In addition, column 2, lines 4-6 describe a preferred ratio of olanzapine to Drug in the composition which may be about one part olanzapine to from about one (1) to about ten (10) parts Drug. Column 6, lines 22-24 provides further support for the composition of added claim 70. Furthermore, column 5, lines 17-25 disclose Tylenol #3, tricyclic antidepressants (for example desipramine, imipramine, amitriptyline, nortriptyline), anticonvulsants (for example, carbamazepine, gabapentin, valproate), serotonin reuptake inhibitors (for example, fluoxetine, paroxetine, citalopram, sertraline), mixed serotonin-norepinephrine reuptake inhibitors (for example venlafaxine, duloxetine), serotonin receptor agonists and antagonists, cholinergic (muscarinic and nicotinic) analgesics, and neurokinin antagonists.
71	pending	Column 5, line 17 discloses Tylenol #3.
72	pending	Column 5, lines 18-19 disclose tricyclic antidepressants (for example desipramine, imipramine, amitriptyline, nortriptyline).
73	pending	Column 5, line 18 discloses desipramine.
74	pending	Column 5, line 18 discloses imipramine.
75	pending	Column 5, line 18 discloses amitriptyline.
76	pending	Column 5, line 19 discloses nortriptyline.
77	pending	Column 5, lines 19-20 disclose anticonvulsants (for example, carbamazepine, gabapentin, valproate).
78	pending	Column 5, line 19 discloses carbamazepine.
79	pending	Column 5, line 20 discloses gabapentin.
80	pending	Column 5, line 20 discloses valproate.
81	pending	Column 5, lines 20-21 disclose serotonin reuptake inhibitors (for example, fluoxetine, paroxetine, citalopram, sertraline).
82	pending	Column 5, line 21 discloses fluoxetine. Column 5, lines 4-6 disclose that the term "Drug Useful in the Treatment of

		Pain” includes a pharmaceutically acceptable salt thereof.
83	pending	Column 5, line 21 discloses paroxetine.
84	pending	Column 5, line 21 discloses citalopram.
85	pending	Column 5, line 21 discloses sertraline.
86	pending	Column 5, lines 22-23 disclose mixed serotonin-norepinephrine reuptake inhibitors (for example venlafaxine, duloxetine).
87	pending	Column 5, line 23 discloses venlafaxine.
88	pending	Column 5, lines 23 discloses duloxetine.
89	pending	Column 7, lines 31-34 disclose that typical compositions are associated with a pharmaceutically acceptable excipient.
90	pending	Column 8, lines 1-3 disclose that tablets are particularly suitable for oral application.
91	pending	Column 7, lines 31-36 disclose that the carrier may be a capsule.